BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 18537103)

  • 1. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
    Natarajan A; Zaman AG; Marshall SM
    Diab Vasc Dis Res; 2008 Jun; 5(2):138-44. PubMed ID: 18537103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
    van Werkum JW; Topcu Y; Postma S; Kelder JC; Hackeng CM; ten Berg JM; Verheugt FW
    Thromb Haemost; 2008 Mar; 99(3):637-9. PubMed ID: 18327417
    [No Abstract]   [Full Text] [Related]  

  • 3. The genetics of antiplatelet drug resistance.
    Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
    Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis in diabetes: a shear flow effect?
    Westein E; Hoefer T; Calkin AC
    Clin Sci (Lond); 2017 Jun; 131(12):1245-1260. PubMed ID: 28592700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet function testing and implications for clinical practice.
    Collet JP; Montalescot G
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus.
    Santilli F; Lapenna D; La Barba S; Davì G
    Free Radic Biol Med; 2015 Mar; 80():101-10. PubMed ID: 25530150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet therapy in type 2 diabetes mellitus.
    Angiolillo DJ
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):124-31. PubMed ID: 17940430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet therapy in patients with diabetes mellitus.
    Grove EL; Gregersen S
    Curr Vasc Pharmacol; 2012 Jul; 10(4):494-505. PubMed ID: 22272895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.
    Coccheri S
    Drugs; 2010 May; 70(7):887-908. PubMed ID: 20426498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelets and antiplatelet therapy in patients with diabetes mellitus.
    Arjomand H; Roukoz B; Surabhi SK; Cohen M
    J Invasive Cardiol; 2003 May; 15(5):264-9. PubMed ID: 12730635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to antiplatelet drugs: current status and future research.
    Tantry US; Bliden KP; Gurbel PA
    Expert Opin Pharmacother; 2005 Oct; 6(12):2027-45. PubMed ID: 16197357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives.
    Kalantzi KI; Tsoumani ME; Goudevenos IA; Tselepis AD
    Expert Rev Clin Pharmacol; 2012 May; 5(3):319-36. PubMed ID: 22697594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet drugs.
    De Meyer SF; Vanhoorelbeke K; Broos K; Salles II; Deckmyn H
    Br J Haematol; 2008 Aug; 142(4):515-28. PubMed ID: 18513285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet biology and implications for antiplatelet therapy in atherothrombotic disease.
    Montalescot G
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):371-80. PubMed ID: 20566574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet activation and progression to complications.
    Kereiakes DJ; Michelson AD
    Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet dysfunction in central obesity.
    Anfossi G; Russo I; Trovati M
    Nutr Metab Cardiovasc Dis; 2009 Jul; 19(6):440-9. PubMed ID: 19346117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.